Phaseline

Targets › DMPK

DMPK (Myotonin-protein kinase): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Neurology; next expected readout Jul 2028.

Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. (UniProt, Q09013)

Open in Phaseline: the race on DMPK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dyne Therapeuticszeleciment basivarsen (DYNE-101)
antisense oligonucleotide targeting DMPK mRNA
DMPKPhase 3Myotonic Dystrophy Type 1 (DM1)Jul 2028

Conditions

Myotonic Dystrophy Type 1 (DM1) (2)

Modalities

other (1)

Companies

Dyne Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.